The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
On November 2, 2025, the research group led by Dr. Zeng Ling from Army Medical University systematically elucidated the molecular mechanisms, ...
Advancing investigational pre-clinical research of APL-9099 3, a potential one-time neonatal Fc receptor (FcRn) treatment ...
Islands.com on MSN
The 14 Best Mountain Airbnbs In The Western United States And Canada
There are plenty of refreshing, mountain getaways in the Western United States and Canada, and some of the best ...
In the sophisticated world of endocrinology and molecular biology, few compounds have sparked as much curiosity as CJC-1295 DAC. As a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), this ...
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback